4 days ago
Indivior Plans to Cancel London Listing After Moving Primary to US
Indivior Plc said it plans to cancel its secondary listing in London nearly a year after the drugmaker shifted its primary trading to the US, marking the latest departure from the UK's capital markets.
The opioid-addiction therapy maker moved its main listing to New York last year in search of more analyst and investor coverage, but had a rocky start amid guidance cuts. It's planning to ditch the secondary trading it had maintained on the London Stock Exchange to better reflect where its revenues come from and eliminate the cost of the secondary listing, given most of its volume and investors are now in the US, according to a statement.
